Patents by Inventor David B. Whitman

David B. Whitman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210284651
    Abstract: Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.
    Type: Application
    Filed: May 25, 2021
    Publication date: September 16, 2021
    Inventors: Robert L. Hudkins, David B. Whitman, Craig A. Zificsak, Allison L. Zulli, Melody McWherter
  • Patent number: 11046707
    Abstract: Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: June 29, 2021
    Assignee: 89BIO LTD
    Inventors: Robert L. Hudkins, David B. Whitman, Craig A. Zificsak, Allison L. Zulli, Melody McWherter
  • Publication number: 20200031840
    Abstract: Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.
    Type: Application
    Filed: December 14, 2017
    Publication date: January 30, 2020
    Inventors: Robert L. HUDKINS, David B. WHITMAN, Craig A. ZIFICSAK, Allison L. ZULLI, Melody MCWHERTER
  • Patent number: 8685961
    Abstract: The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: April 1, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Karen M. Brashear, Paul J. Coleman, Christopher D. Cox, Anthony M. Smith, David B. Whitman
  • Patent number: 8669272
    Abstract: The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: March 11, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, John D. Schreier, David B. Whitman
  • Patent number: 8263586
    Abstract: The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Grant
    Filed: May 14, 2008
    Date of Patent: September 11, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher D. Cox, David B. Whitman
  • Publication number: 20110319409
    Abstract: The present invention is directed to 7-aza-quinazoline compounds of general structural formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10).
    Type: Application
    Filed: June 23, 2010
    Publication date: December 29, 2011
    Inventors: Christopher D. Cox, Izzat T. Raheem, Broc A. Flores, David B. Whitman
  • Publication number: 20110251237
    Abstract: The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 15, 2009
    Publication date: October 13, 2011
    Applicant: MERCK SHARP & DOHME CROP.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, John D. Schreier, David B. Whitman
  • Publication number: 20100227848
    Abstract: The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: May 14, 2008
    Publication date: September 9, 2010
    Inventors: Christopher D. Cox, David B. Whitman
  • Publication number: 20100029736
    Abstract: The present invention is directed to 2-substituted proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: July 13, 2007
    Publication date: February 4, 2010
    Applicant: MERCK & CO., INC.
    Inventors: Christopher D. Cox, David B. Whitman, Michael J. Breslin
  • Publication number: 20090258903
    Abstract: The present invention is directed to aminoethane sulfonamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: July 31, 2006
    Publication date: October 15, 2009
    Inventors: Paul J. Coleman, Christopher D. Cox, David B. Whitman
  • Patent number: 7595337
    Abstract: The present invention relates to tricyclic pyrazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: September 29, 2009
    Assignee: Merck & Co. Inc.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, Lou Anne Neilson, David B. Whitman
  • Publication number: 20090176789
    Abstract: The present invention is directed to diazaspirodecane compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: August 24, 2006
    Publication date: July 9, 2009
    Inventors: Michael J. Breslin, Christopher D. Cox, David B. Whitman
  • Publication number: 20090124603
    Abstract: The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: March 27, 2007
    Publication date: May 14, 2009
    Inventors: Karen M. Brashear, Paul J. Coleman, Christopher D. Cox, Anthony M. Smith, David B. Whitman
  • Publication number: 20090118200
    Abstract: The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: May 22, 2006
    Publication date: May 7, 2009
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Christopher D. Cox, George D. Hartman, Craig Lindsley, Swati Pal Mercer, Anthony J. Roecker, David B. Whitman
  • Publication number: 20080182843
    Abstract: The present invention relates to tricyclic pyrazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: February 6, 2006
    Publication date: July 31, 2008
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, Lou Anne Neilson, David B. Whitman
  • Patent number: 7402577
    Abstract: Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 22, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Jiabing Wang, Mark E. Duggan, David B. Whitman
  • Publication number: 20040220159
    Abstract: Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue.
    Type: Application
    Filed: March 30, 2004
    Publication date: November 4, 2004
    Inventors: Jiabing Wang, Mark E. Duggan, David B. Whitman
  • Patent number: 5648368
    Abstract: Novel fibrinogen receptor antagonists of the formula:X--Y--Z--Aryl--A--Bare provided in which the claimed compounds exhibit fibrinogen receptor antagonist activity, inhibit platelet aggregation and are therefore useful in modulating thrombus formation.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 15, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Melissa S. Egbertson, Laura M. Vassallo, George D. Hartman, Wasyl Halczenko, David B. Whitman, James J. Perkins, Amy E. Krause, Nathan Ihle, David Alan Claremon, William Hoffman, Mark E. Duggan